Functional Neurological Disorder Market

Market Overview:

The 7 major functional neurological disorder markets reached a value of US$ 10.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 23.1 Billion by 2034, exhibiting a growth rate (CAGR) of 7.53% during 2024-2034.

The functional neurological disorder market has been comprehensively analyzed in IMARC's new report titled "Functional Neurological Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Functional neurological disorder refers to a complex and multifactorial condition that affects the functioning of the nervous system. The disease can lead to a disconnect between the brain and the body, resulting in several physical signs that can be distressing and debilitating. The symptoms of this ailment can vary widely and may affect various processes related to the body, such as motor, sensory, and cognitive functions. Some common indications associated with the disease include weakness or paralysis of limbs, tremors, irregular movements, gait abnormalities, trouble with attention, concentration, or coordination, memory issues, chronic pain, confusion, numbness, tingling, or loss of feeling in the affected region, vision problems, etc. The diagnosis of this condition mainly relies on the identification of certain clinical features that distinguish it from organic neurological disorders, such as the inconsistency of symptoms, incongruity with known neurological patterns, presence of psychological factors, etc. Additionally, a healthcare professional may perform numerous imaging studies, like magnetic resonance imaging (MRI) or computed tomography (CT) scans, to rule out structural abnormalities or various other organic causes of the indications. 

The increasing prevalence of dysfunctions in the neural networks, which can lead to alterations in brain activity and connectivity patterns, is primarily driving the functional neurological disorder market. In addition to this, the rising incidence of psychological trauma, such as sexual or physical abuse, that affects the processing and interpretation of sensory information within the brain is also creating a positive outlook for the market. Moreover, the widespread adoption of mind-body therapies, which involve relaxation exercises, meditation, mindfulness, and yoga to minimize stress and improve overall well-being, is further bolstering the market growth. Apart from this, the inflating application of selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, sertraline, escitalopram, etc., owing to their several advantages, like reducing disease symptoms and enhancing the brain's adaptive responses, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of cognitive-behavioral therapy, which helps to identify and challenge negative or distorted thinking patterns, thereby decreasing emotional distress in individuals suffering from the ailment, is expected to drive the functional neurological disorder market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the functional neurological disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for functional neurological disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the functional neurological disorder market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the functional neurological disorder market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the functional neurological disorder market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current functional neurological disorder marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the functional neurological disorder market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the functional neurological disorder market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the functional neurological disorder market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of functional neurological disorder across the seven major markets?
• What is the number of prevalent cases (2018-2034) of functional neurological disorder by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of functional neurological disorder by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with functional neurological disorder across the seven major markets?
• What is the size of the functional neurological disorder patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of functional neurological disorder?
• What will be the growth rate of patients across the seven major markets?
   

Functional Neurological Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for functional neurological disorder drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the functional neurological disorder market?
• What are the key regulatory events related to the functional neurological disorder market?
• What is the structure of clinical trial landscape by status related to the functional neurological disorder market?
• What is the structure of clinical trial landscape by phase related to the functional neurological disorder market?
• What is the structure of clinical trial landscape by route of administration related to the functional neurological disorder market?